Introduction
Despite the surge in our knowledge of Fabry's Disease (FD) and the advancements in diagnostic tools, there is often a significant time between the onset of symptoms and diagnosis. According to the Fabry Registry, 10.5 years is the average age of symptom onset, but 28.5 years is the average age of diagnosis. As a rare disease which shares clinical manifestations with many other disorders, FD can be challenging to recognize. This is a concern because early initiation of enzyme replacement therapy has been found to be important for reduction of disease burden. In order to help clinicians identify FD in its earliest stages, in this review we describe its neurological features, diagnosis and treatment.
Characteristic features of neuropathy in Fabry's disease:
Neuropathy in FD is a small fiber neuropathy (SFN), affecting small myelinated and unmyelinated neurons. The characteristic neuropathy of FD is a symmetrical, length-dependent sensory polyneuropathy which starts in the feet and spreads proximally. In FD the Aδ fibers are preferentially affected, which is in contrast to most other SFNs where both Aδ-and C-fibers are affected 
Clinical presentation
Symptoms usually begin between the ages of 3 to 10 years, with males affected earlier and more severely than females [2] [3] [4] . FD is divided into "classical" and "non-classical" or "atypical" varieties. Burning pain, hypo or hyperhidrosis, transient ischemic attacks, strokes, angiokeratoma, proteinuria, cardiomyopathy, arrhythmia, cochleovestibular and gastrointestinal disorders are the most common presenting features in "classically" affected hemizygous males who have no residual α-galactosidase A activity 4 . Patients with "nonclassical" or "atypical" disease who have residual α-galactosidase A activity exhibit milder disease, and typically present in the fourth to sixth decades with clinical manifestations confined to one organ system 5, 6 .
Pain in FD
The second type is chronic pain, which is characterized by burning, shooting pain or dysesthesias in the hands or feet 9, 10 . Decrease in pain with ageing occurs in some patients 11 . This may occur as a consequence of progressive small fiber damage with changes in neural function leading to a decrease in pain 12 . Therefore when pain is not an active symptom, it is important to inquire about a history of acroparesthesias in childhood.
Other sensory manifestations
There is loss of temperature sensation in the hands and feet and reduced tolerance to cold 
Autonomic nervous system involvement
There is controversy whether autonomic neuropathy is a major feature of FD. Since FD causes relatively selective damage to Aδ fibers, autonomic functions are usually preserved 14 . Sweat glands [14] [15] [16] [17] [18] [19] , dermal nerve endings 9 , vessel response 20 , heart rate variability 21 , orthostatic blood pressure, and male sexual function are usually normal 22 . These observations suggest that it is unlikely that FD patients suffer significant autonomic neuropathy. A Four-year prospective clinical trial found remarkable improvement in all heart rate variability indices in boys undergoing agalsidase alfa replacement therapy 23 .There are a few reports of orthostatic hypotension and syncope in patients with FD, suggesting localized cardiovascular autonomic abnormalities 24, 25 . However, these and other abnormal studies of peripheral hemodynamics might be explained by end-organ failure such as stiffness of vascular smooth muscle and endothelial dysfunction 26 .
Cerebrovascular disease
In FD there is a significant incidence of stroke, which is mostly small vessel ischemic event 27 , and there is also a predilection for acute ischemia in the posterior cerebral circulation 28, 29 . Among different MRI changes, the finding of hyper-intensity in the pulvinar on T1 weighted images ("pulvinar sign") has been found to be a highly specific sign in FD 30 ( Fig. 1) . The most common angiographic findings are tortuous, elongated, ectatic vertebral and basilar arteries. Increased basilar artery diameter is 87% accurate in diagnosing FD 31 . Cerebral blood flow changes may result in increased white matter interstitial pressure and metabolic impairment 32 . Cerebral involvement is usually widespread. The posterior cerebrum is predominantly involved 32 . Chiari type I malformation has been found in some patients with FD
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.
Hearing loss
There is a high incidence of progressive hearing loss, mainly sensorineural with vestibular dysfunction and sudden deafness in male patients with FD
34
Diagnosis

When to suspect Fabry's disease
To diagnose FD, further specific tests are recommended by the National Society of Genetic Counselors for patients with any of the factors outlined in Table 1 .
Diagnostic testing
In males, the diagnosis is based on typical FD signs and symptoms, very low or completely absent α-galactosidase A (GLA) activity in leukocytes, plasma or fibroblasts, increased globotriaosylceramide (Gb3) and lyso-Gb3 concentrations in plasma and urine and a pathogenic mutation on genetic analysis 29, 36, 37 (Figure 2) 1 . Females affected by FD have α-galactosidase A levels which can range from deficient to normal 3, [38] [39] [40] . Therefore, diagnosis must rely upon molecular analysis to identify a disease Neonatal screening for FD in males is technically feasible by measurement of α-galactosidase A activity in dried blood spot (DBS) using either the fluorogenic or mass spectrometric substrate and will detect cases both with complete deficiency and residual enzyme activity 43 .
Neurologic testing
Conventional nerve conduction studies (NCS) assess only large myelinated nerve fibers, and are usually normal in FD unless renal failure is present. Quantitative sensory testing (QST), quantitative sudomotor axon reflex test (QSART) and skin biopsy to assess epidermal nerve fiber density (ENFD) are useful to confirm the presence of SFN. Recently, pain-related evoked potentials (PREPs), where electrical current using special concentric electrodes 44 is used to stimulate A-delta fibers, was described as a suitable and easily applicable new tool for objective small fiber diagnostics 45 . SFN in FD has been demonstrated to be length dependent by using proximal and distal skin biopsy sites 46 . Corneal nerve fiber density (C-fibers) and corneal sensation has been demonstrated to be significantly reduced 47 . Some studies concluded that sensory impairment and SF pathology in FD patients are gender-dependent, associated with reduced renal function, and are progressive in most patients despite ERT 48, 49 .
Differential diagnosis
For clinicians, it is of utmost importance to distinguishing FD from other causes of painful small-fiber neuropathy (Table 2) 1 .
Management Enzyme replacement therapy (ERT)
ERT is currently the standard of care for FD patients. The most current literature emphasizes that ERT should be instituted upon confirming the diagnosis of FD. Recombinant human α-galactosidase A is commercially available in two forms given as an intravenous (IV) infusion every two weeks. Agalsidase alfa (Replagal) and Agalsidase beta (Fabrazyme) are the two commercially available preparations. Agalsidase beta is approved for use in the United States (US). Agalsidase alfa, on the other hand, is not approved for use in the US. Although complications such as stroke and renal damage may still occur while receiving ERT, patients with FD were found to benefit from ERT, particularly when started at earlier stages of the disease before end organ damage occurs 51 .
Infusion related reactions and neutralizing IgG antibodies with ERT
Adverse effects of ERT include fever, chills, facial flushing and rigors. Infusion reactions are managed conservatively with antihistamines and corticosteroids in cases of a severe reaction. Neutralizing IgG antibodies may develop to agalsidase alfa and beta and show cross reactivity between the two enzyme replacements [52] [53] [54] . It is recommended that patients receiving ERT should be checked for serum neutralizing antibodies every three months during the first year and then yearly 55 .
Pain management
Anti-epileptic drugs are widely used for pain control in patients with FD. Treatment using combinations of anti-epileptic drugs may be necessary for adequate pain control 56 . Treatment with agalsidase beta resulted in decreased neuropathic pain and improved function of Aδ, C and Aβ nerve fibers and intradermal vibratory receptors detected by QST 57, 58 . Analgesic medications can also be used, but nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided since they are not effective and potentially harmful to kidneys 59 . In an effort to provide practical pain management guidelines for FD in adults, an FD Expert Panel suggested recommendations that are summarised in Table 3 60 .
Peripheral nervous system
Agalsidase alfa therapy has been shown to achieve lower heat pain thresholds, improved cold detection threshold, and improvement of sympathetic skin responses with associated improvement in acroparesthesia and anhidrosis 57, 58, 61, 62 . Treatment with agalsidase beta resulted in improved function of Aδ, C and Aβ nerve fibers and intradermal vibratory receptors detected by QST 57, 58 .
Cerebrovascular system
Neither agalsidase alfa nor beta has been shown to reduce the frequency of cerebrovascular events 63 . Possible reasons are that neither of the available enzyme compounds cross the blood brain barrier and that irreversible damage to the endothelium typically occurs before the initiation 
Pharmacological chaperone therapy
Migalastat was recently approved by the European commission for treatment of FD patients aged 16 years and older, but not yet approved in the US. It works by facilitating appropriate trafficking of GLA to lysosomes. Migalastat is orally administered, thus it is less invasive than ERT IV infusion. Reduction in plasma lyso-Gb3 levels and improvement in kidneys, heart and gastrointestinal tract functions, have been reported in patients with suitable mutations. No sufficient evidence was found for the effect of Migalastat on neurological manifestations of FD 64 .
Conclusion
FD is rare and shows diverse symptoms in the initial stages of manifestation; therefore, the definitive diagnosis is often delayed. However, in recent years, FD has become more widely recognized and there has been a considerable advance in the diagnosis and treatment options. The response to ERT is dependent on the severity of organ involvement, and better results occur when the treatment is instituted early in the disease before major organ damage has occurred.
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